שלח לחבר תודה לך על המלצתך על e-Med לחבר

	24/07/2021

01/12/2018

תגובה לטיפול ב-Secukinumab בחולים עם Ankylosing Spondylitis אינה תלויה ברמות סמני דלקת (RMD Open)

44<P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><?xml:namespace prefix = "o" ns = "urn:schemas-microsoft-com:office:office" /><o:p> </o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'>בחולים עם </SPAN><FONT face=Calibri><SPAN dir=ltr>Ankylosing Spondylitis</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> (</SPAN><FONT face=Calibri><SPAN dir=ltr>AS</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN>) תועדה תגובה דומה לטיפול ב-</SPAN><SPAN dir=ltr></SPAN><SPAN lang=HE dir=ltr><SPAN dir=ltr></SPAN><FONT face=Calibri> </FONT></SPAN><SPAN dir=ltr><A href="https://data.health.gov.il/drugs/index.html#/medDetails"><FONT color=#0000ff><FONT face=Calibri>Secukinumab<SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi' dir=rtl><SPAN dir=rtl></SPAN> (קוסנטיקס)</SPAN></FONT></A></SPAN><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'>, ללא תלות ברמות </SPAN><FONT face=Calibri><SPAN dir=ltr>CRP</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> (</SPAN><FONT face=Calibri><SPAN dir=ltr>C-Reactive Protein</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN>) ובין אם אלו היו תקינות או גבוהות, כך עולה מנתונים חדשים, שפורסמו בכתב העת </SPAN><FONT face=Calibri><SPAN dir=ltr>RMD Open: Rheumatic Musculoskeletal Diseases</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN>.<o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><o:p> </o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'>להערכת התגובה לטיפול ב-</SPAN><SPAN dir=ltr></SPAN><SPAN lang=HE dir=ltr><SPAN dir=ltr></SPAN><FONT face=Calibri> </FONT></SPAN><FONT face=Calibri><SPAN dir=ltr>Secukinumab</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN>, בהתאם לרמות </SPAN><FONT face=Calibri><SPAN dir=ltr>CRP</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN>, החוקרים בחנו את הנתונים משני מחקרים בנושא, </SPAN><FONT face=Calibri><SPAN dir=ltr>MEASURE 1</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> ו-</SPAN><FONT face=Calibri><SPAN dir=ltr>MEASURE 2</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN>, כולל 392 חולים עם </SPAN><FONT face=Calibri><SPAN dir=ltr>AS</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> פעיל, אשר קיבלו זריקות תת-עוריות של </SPAN><FONT face=Calibri><SPAN dir=ltr>Secukinumab</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> במינון 150 מ"ג, או פלסבו, אשר ניתנו כל ארבעה שבועות. מאחר והסף המדווח לרמות </SPAN><FONT face=Calibri><SPAN dir=ltr>CRP</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> מוגברות הינו 5-8 מ"ג/ליטר, החוקרים בחנו את התגובה לפי שני ספים – 5 מ"ג/ליטר ו-10 מ"ג/ליטר. <o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><o:p> </o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'>החוקרים מדווחים כי ב-63.5% מהחולים תועדו רמות </SPAN><FONT face=Calibri><SPAN dir=ltr>CRP</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> של 5 מ"ג/ליטר ומעלה, בעוד שביתר החולים רמות </SPAN><FONT face=Calibri><SPAN dir=ltr>CRP</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> היו מתחת לסף זה. <o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><o:p> </o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'>המאפיינים הבסיסיים של חולים עם רמות </SPAN><FONT face=Calibri><SPAN dir=ltr>CRP</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> תקינות או מוגברות היו דומים, כאשר מרבית החולים היו גברים. גיל המשתתפים הממוצע עמד על 43.8 שנים ו-41 שנים, בהתאמה, עם משך מחלה של 7 ו-7.2 שנים, בהתאמה. <o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><o:p> </o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'>לאחר 16 שבועות, שיעורי התגובה לפי</SPAN><FONT face=Calibri><SPAN dir=ltr>ASAS40 </SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN><SPAN style="mso-spacerun: yes"> </SPAN>עמדו על 34.7% בקבוצת החולים עם רמות </SPAN><FONT face=Calibri><SPAN dir=ltr>CRP</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> תקינות אשר טופלו ב-</SPAN><SPAN dir=ltr></SPAN><SPAN lang=HE dir=ltr><SPAN dir=ltr></SPAN><FONT face=Calibri> </FONT></SPAN><FONT face=Calibri><SPAN dir=ltr>Secukinumab</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN>, לעומת 7% באלו בקבוצת הפלסבו (</SPAN><FONT face=Calibri><SPAN dir=ltr>P<0.001</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN>) ועל 42.4% לעומת 15.3% באלו עם רמות </SPAN><FONT face=Calibri><SPAN dir=ltr>CRP</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> מוגברות (</SPAN><FONT face=Calibri><SPAN dir=ltr>p<0.0001</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN>). בעוד שהתגובות היו גבוהות יותר באופן עקבי בחולים שטופלו ב-</SPAN><SPAN dir=ltr></SPAN><SPAN lang=HE dir=ltr><SPAN dir=ltr></SPAN><FONT face=Calibri> </FONT></SPAN><FONT face=Calibri><SPAN dir=ltr>Secukinumab</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN>, היקף התגובה היה גדול יותר בקרב חולים עם רמות </SPAN><FONT face=Calibri><SPAN dir=ltr>CRP</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> מוגברות.<o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><o:p> </o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'>לפי מדד </SPAN><FONT face=Calibri><SPAN dir=ltr>BASDAI</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> (</SPAN><FONT face=Calibri><SPAN dir=ltr>Bath Ankylosing Spondylitis Disease Activity Index</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN>), השינוי בממוצע הריבועים הפחותים מתחילת המחקר עד לאחר 16 שבועות עמד על 2.2- ו-2.4- בקבוצת הטיפול ב-</SPAN><SPAN dir=ltr></SPAN><SPAN lang=HE dir=ltr><SPAN dir=ltr></SPAN><FONT face=Calibri> </FONT></SPAN><FONT face=Calibri><SPAN dir=ltr>Secukinumab</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> עם רמות </SPAN><FONT face=Calibri><SPAN dir=ltr>CRP</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> <SPAN lang=HE>תקינות ומוגברות, בהתאמה, ועל 1- ו-0.6-, בהתאמה, בקבוצת הפלסבו.<o:p></o:p></SPAN></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><o:p> </o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'>יתרה מזאת, בשיעור גבוה יותר של מטופלים ב-</SPAN><SPAN dir=ltr></SPAN><SPAN lang=HE dir=ltr><SPAN dir=ltr></SPAN><FONT face=Calibri> </FONT></SPAN><FONT face=Calibri><SPAN dir=ltr>Secukinumab</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> <SPAN lang=HE>תועדה מחלה לא-פעילה לאחר 16 שבועות לפי מדד </SPAN></SPAN><FONT face=Calibri><SPAN dir=ltr>ASDAS</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> (</SPAN><FONT face=Calibri><SPAN dir=ltr>AS Disease Activity Score</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN>), בהשוואה לפלסבו בחולים עם </SPAN><FONT face=Calibri><SPAN dir=ltr>CRP</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> תקין (19.4% לעומת 4.2%, </SPAN><FONT face=Calibri><SPAN dir=ltr>p<0.05</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN>) ורמות </SPAN><FONT face=Calibri><SPAN dir=ltr>CRP</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> מוגברות (15.2% לעומת 2.4%, </SPAN><FONT face=Calibri><SPAN dir=ltr>p<0.01</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN>). <o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><o:p> </o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'>שיפורים אלו במדד </SPAN><FONT face=Calibri><SPAN dir=ltr>BASDAI</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> ושיעורי מחלה לא-פעילה לפי </SPAN><FONT face=Calibri><SPAN dir=ltr>ASDAS</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> נותרו לאורך זמן או השתפרו לאורך 156 שבועות טיפול ב-</SPAN><SPAN dir=ltr></SPAN><SPAN lang=HE dir=ltr><SPAN dir=ltr></SPAN><FONT face=Calibri> </FONT></SPAN><FONT face=Calibri><SPAN dir=ltr>Secukinumab</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> בשתי הקבוצות, אלו עם רמות </SPAN><FONT face=Calibri><SPAN dir=ltr>CRP</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> תקינות או מוגברות. תוצאות דומות תועדו כאשר החוקרים קבעו סף </SPAN><FONT face=Calibri><SPAN dir=ltr>CRP</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> על 10 מ"ג/ליטר. <o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><o:p> </o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'>מהנתונים עולה כי בחולים עם רמות </SPAN><FONT face=Calibri><SPAN dir=ltr>CRP</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN> תקינות תועד סיכוי גבוה יותר לתגובה חיובית לטיפול ב-</SPAN><SPAN dir=ltr></SPAN><SPAN lang=HE dir=ltr><SPAN dir=ltr></SPAN><FONT face=Calibri> </FONT></SPAN><FONT face=Calibri><SPAN dir=ltr>Secukinumab</SPAN><SPAN dir=rtl></SPAN></FONT><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><SPAN dir=rtl></SPAN>. <o:p></o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><o:p> </o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><FONT face=Calibri><SPAN dir=ltr>RMD Open 2018</SPAN><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><o:p></o:p></SPAN></FONT></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><o:p> </o:p></SPAN></P> <P class=MsoNormal style="MARGIN: 0cm 0cm 0pt" dir=rtl><SPAN lang=HE style='FONT-FAMILY: "Arial","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi'><A href="https://www.medpagetoday.com/rheumatology/backpain/76585"><FONT color=#0000ff>לידיעה ב-<SPAN lang=EN-US style='FONT-FAMILY: "Calibri","sans-serif"; mso-ascii-font-family: Calibri; mso-ascii-theme-font: minor-latin; mso-hansi-font-family: Calibri; mso-hansi-theme-font: minor-latin; mso-bidi-font-family: Arial; mso-bidi-theme-font: minor-bidi' dir=ltr>MedPage Today</SPAN></FONT></A><o:p></o:p></SPAN></P>

כתובת נמען
נושא
שמך
כתובת הדואר שלך
הערה
	סגור חלון